Generate Biomedicines, Inc.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) None.

(b) On February 26, 2026, the SEC declared effective the Company's registration statement on Form S-1 (File No. 333-293204), as amended, filed in connection with the Company's IPO (the “Registration Statement”). Pursuant to the Registration Statement, we issued and sold 25,000,000 shares of our common stock at a price to the public of $16.00 per share. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as representatives of the underwriters for the IPO. We raised aggregate net proceeds of $369.3 million, after deducting underwriter discounts, commissions and other IPO expenses.

In connection with our IPO, no payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.

We are holding a significant portion of the balance of the net proceeds in a variety of capital preservation investments, including money market funds and U.S. government securities. There has been no material change in the planned use of the net proceeds from our IPO, as described in our final prospectus filed with the SEC on February 27, 2026 pursuant to Rule 424(b) under the Securities Act.

(c) None.